OrthoPediatrics (KIDS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $42.00 price target.
Michael Matson has given his Buy rating due to a combination of factors that highlight OrthoPediatrics’ promising growth prospects. The company’s fourth-quarter revenue for 2024 was in line with prior expectations, and its adjusted EBITDA met consensus estimates, indicating stable financial performance.
Matson notes several growth drivers for OrthoPediatrics, including increased procedure volumes in the US, the introduction of new products, expansion of clinics, opening of new accounts, and international growth. These factors are expected to sustain the company’s strong revenue growth into 2025, reinforcing the Buy rating.
Matson covers the Healthcare sector, focusing on stocks such as Hologic, Merit Medical Systems, and Atricure. According to TipRanks, Matson has an average return of -6.7% and a 38.48% success rate on recommended stocks.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $44.00 price target.